|
|
|
|
LEADER |
05397nmm a2200301 u 4500 |
001 |
EB000622671 |
003 |
EBX01000000000000000475753 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
140122 ||| eng |
020 |
|
|
|a 9781461343493
|
100 |
1 |
|
|a Hellmann, Kurt
|e [editor]
|
245 |
0 |
0 |
|a Chemotherapy
|h Elektronische Ressource
|b Volume 7 Cancer Chemotherapy I
|c edited by Kurt Hellmann
|
250 |
|
|
|a 1st ed. 1976
|
260 |
|
|
|a New York, NY
|b Springer US
|c 1976, 1976
|
300 |
|
|
|a XII, 364 p
|b online resource
|
505 |
0 |
|
|a Intracavitary Glioma Chemotherapy -- Screening on Enzyme Inhibitors with Potential Antitumour Activity -- Recent Experience with Microbial Systems and Cancer Cells In Vitro in the Screening for Antitumor Antibiotics -- Problems Related to the Detection of Activity of Antitumour Antibiotics -- Attempts to Overcome Methotrexate Resistance: The Value of Drug Resistant Cell Lines -- In Vitro Mutagenesis by Anti-Cancer Drugs -- In Vitro Systems Using Micro-Organisms for Detection of Carcinogenic Agents -- In Vitro Screening of Cytotoxic Substances Using Different Tumour Cells -- In Vitro Methods for Use in Drug Metabolism Studies -- Some Problems in the Use of Short Term Cultures of Human Tumours for In Vitro Screening of Cytotoxic Drugs -- Combination of Corynebacterium parvum and Cytostatic Drugs in Disseminated Human Cancers -- Radiotherapy and Chemotherapy in Acute Leukaemia Related to Fatal Infection During Remission -- The Target Cell of Immunosuppressive Agents --
|
505 |
0 |
|
|a Immunological Aspects of Anticancer Drugs -- List of Contributors
|
505 |
0 |
|
|a Advances in Cancer Chemotherapy -- Experimental Basis of Cancer Chemotherapy -- New Leads Towards Antitumor Selectivity in Therapeutics -- An Experimental Approach to Increase Selective Tumour Toxicity of Methotrexate -- Alterations in Intracellular Cyclic AMP as a Potential Form of Antitumour Chemotherapy -- The Drug-Carrier Potential of Liposomes in Cancer Chemotherapy -- Significance of Prostaglandins in Tumour Growth -- Oestrogen Binding as a Predictive Test for DMBA-Induced Tumour Response to Tamoxifen Therapy -- Action of Anticancer Drugs on the Cell Cycle. Chromosome Damage and Differential Stage Sensitivity -- Adriamycin Metabolism in Man -- Pharmacokinetics of Anticancer Drugs -- Pharmacokinetics and Metabolism of Anticancer Drugs -- The Activity of New Drugs Against Mouse Tumours -- Platinum Complexes as Anticancer Drugs -- Streptozotocin, Chlorozotocin, and Related Nitrosourea Antitumour Agents -- Analogues and Metabolites of Cyclophosphamide --
|
505 |
0 |
|
|a ICRF 159 and Other Bisdioxopiperazines -- Biological Basis of Radiosensitization by Hypoxic-Cell Radiosensitizers -- Bleomycin and Radiotherapy -- Experience with ICRF 159 and Radiotherapy in Combination in the Treatment of Soft Tissue Sarcomas -- Metronidazole (Flagyl) in Cancer Radiotherapy -- Possibilities of the Human Tumour/Nude Mouse System in Cancer Chemotherapy Research -- Chemotherapy of Transplantable Colon Tumours in Mice -- Utilization of Nitrosamine-Indueed Tumours as Models for Cancer Chemotherapy -- The Production of Osteolytic Substances by Human Breast Tumours -- The Biological Basis of Combination Chemotherapy -- Combination Chemotherapy of Advanced Gastrointestinal Carcinoma -- Combination Chemotherapy in Breast and Lung Cancer -- Chemotherapy of CNS Tumors -- Nitrosoureas: Clinical and Experimental Considerations in the Treatment of Brain Tumors -- Effect of CCNU on Survival, Objective Remissions, and Free Interval in Patients with Malignant Gliomas --
|
653 |
|
|
|a Pharmacology
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
490 |
0 |
|
|a Chemotherapy
|
028 |
5 |
0 |
|a 10.1007/978-1-4613-4349-3
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4613-4349-3?nosfx=y
|x Verlag
|3 Volltext
|
082 |
0 |
|
|a 615
|
520 |
|
|
|a The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur rent progress in chemotherapy
|